Photo by nci from unsplash
Chronic spontaneous urticaria (CSU) is a mast cell‐mediated disease, which is sometimes associated with various inflammatory disorders. Omalizumab is a commonly used biological agent, which is a recombinant, humanized, monoclonal… Click to show full abstract
Chronic spontaneous urticaria (CSU) is a mast cell‐mediated disease, which is sometimes associated with various inflammatory disorders. Omalizumab is a commonly used biological agent, which is a recombinant, humanized, monoclonal antibody against human immunoglobulin E. However, there are only few reports about the combination of omalizumab for CSU with any other biologics for accompanying inflammatory diseases in the literature. The aim of this study was to evaluate the patients whose treatment of omalizumab for CSU were combined with any other biologics for associated inflammatory disorders and to describe whether these combinations might have any safety concerns.
Journal Title: Australasian Journal of Dermatology
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!